Correction to: Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis (Alzheimer's Research & Therapy, (2024), 16, 1, (228), 10.1186/s13195-024-01594-6)

Abstract

Correction: Alz Res Therapy 16, 228 (2024) Following publication of the original article [1], an important textual error was noticed and corrected in the fourth paragraph of Background section. The current wording erroneously states that CETP inhibitors decreases Apo-E concentration: However, all CETP inhibitors, including the novel CETP-inhibitor obicetrapib, lowers plasma concentrations of apolipoprotein-E (Apo-E) [4] which is a known risk factor for dementia, in particular for Alzheimer’s disease (AD). Whereas the cited reference [4] actually shows an increasing effect. The correct wording should read: However, all CETP inhibitors, including the novel CETP-inhibitor obicetrapib, increase plasma concentrations of apolipoprotein-E (Apo-E) [4], which is associated with decreased risk of dementia, in particular for Alzheimer’s disease (AD). The original article [1] has been updated.